DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
Status:
Completed
Trial end date:
2020-12-11
Target enrollment:
Participant gender:
Summary
The primary purpose of this trial is to compare the efficacy and safety of DS-8201a and
physician's choice treatment in HER2-overexpressing advanced gastric or gastroesophageal
junction adenocarcinoma patients who have progressed on two prior treatment regimens
including fluoropyrimidine agent, platinum agent, and trastuzumab.